Literature DB >> 25952249

Neurocognitive and neuroimaging outcome of early treated young adult PKU patients: A longitudinal study.

Francesca Nardecchia1, Filippo Manti2, Flavia Chiarotti3, Claudia Carducci4, Carla Carducci5, Vincenzo Leuzzi6.   

Abstract

The aim of the study was to explore the outcome of neurocognitive deficits and neuroimaging correlates in young adult early treated phenylketonuric (PKU) patients. We conducted a longitudinal study of 14 PKU patients that were assessed for IQ and neuropsychological functioning including executive functions (EF) over 14 years of follow-up (age range at 1st and 2nd assessments were 7.8-13.5 and 22.2-27.7 years, respectively). The IQ of all 14 PKU patients was within the normal range. With respect to the 1st assessment, mean IQ at follow-up did not decrease significantly. Compared to control subjects (n = 14), mean IQ of patients was significantly lower (p = .0005). Throughout adolescence and early adulthood there was an improvement of neuropsychological functioning of PKU patients in spite of the relaxation of diet, however some deficits were still detectable when compared to controls. All patients that underwent a second MRI scan showed white matter alterations ranging from mild to severe which was correlated neither with IQ nor with EF scoring. Cognitive, neuropsychological and neuroimaging outcome was influenced from life-long and/or second decade of life metabolic control. Nevertheless patients' developmental trajectories were in some cases independent from metabolic control. Our results support the hypothesis of an individual vulnerability to phenylalanine. However, as long as individual factors that account for the vulnerability to Phe are not recognized, strict dietary control is recommended for all the patients also in the second decade of life.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Executive function; Phenylalanine; Vulnerability; White matter alteration

Mesh:

Substances:

Year:  2015        PMID: 25952249     DOI: 10.1016/j.ymgme.2015.04.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  25 in total

1.  The influence of blood phenylalanine levels on neurocognitive function in adult PKU patients.

Authors:  A Bartus; F Palasti; E Juhasz; E Kiss; E Simonova; Cs Sumanszki; P Reismann
Journal:  Metab Brain Dis       Date:  2018-06-12       Impact factor: 3.584

2.  Predictability and inconsistencies in the cognitive outcome of early treated PKU patients.

Authors:  Filippo Manti; Francesca Nardecchia; Sabrina Paci; Flavia Chiarotti; Claudia Carducci; Carla Carducci; Silvia Dalmazzone; Graziella Cefalo; Elisabetta Salvatici; Giuseppe Banderali; Vincenzo Leuzzi
Journal:  J Inherit Metab Dis       Date:  2017-08-23       Impact factor: 4.982

3.  Neurocognitive profiles in MSUD school-age patients.

Authors:  Juliette Bouchereau; Julie Leduc-Leballeur; Samia Pichard; Apolline Imbard; Jean-François Benoist; Marie-Thérèse Abi Warde; Jean-Baptiste Arnoux; Valérie Barbier; Anaïs Brassier; Pierre Broué; Aline Cano; Brigitte Chabrol; Gilles Damon; Claire Gay; Isabelle Guillain; Florence Habarou; Delphine Lamireau; Chris Ottolenghi; Laetitia Paermentier; Frédérique Sabourdy; Guy Touati; Hélène Ogier de Baulny; Pascale de Lonlay; Manuel Schiff
Journal:  J Inherit Metab Dis       Date:  2017-03-21       Impact factor: 4.982

4.  Altered tetrahydrobiopterin metabolism in patients with phenylalanine hydroxylase deficiency.

Authors:  Francesca Nardecchia; Flavia Chiarotti; Claudia Carducci; Silvia Santagata; Giulia Valentini; Antonio Angeloni; Nenad Blau; Vincenzo Leuzzi
Journal:  Eur J Pediatr       Date:  2017-05-24       Impact factor: 3.183

5.  cAMP/PKA-CREB-BDNF signaling pathway in hippocampus of rats subjected to chemically-induced phenylketonuria.

Authors:  Cigdem Cicek; Emine Eren-Koçak; Pelin Telkoparan-Akillilar; Muslum Gok; Ebru Bodur
Journal:  Metab Brain Dis       Date:  2021-11-20       Impact factor: 3.584

Review 6.  Phenylketonuria.

Authors:  Francjan J van Spronsen; Nenad Blau; Cary Harding; Alberto Burlina; Nicola Longo; Annet M Bosch
Journal:  Nat Rev Dis Primers       Date:  2021-05-20       Impact factor: 52.329

7.  Long-Term Neurological Outcomes of Adult Patients with Phenylketonuria before and after Newborn Screening in Japan.

Authors:  Kenji Yamada; Seiji Yamaguchi; Kazunori Yokoyama; Kikumaro Aoki; Takeshi Taketani
Journal:  Int J Neonatal Screen       Date:  2021-04-14

8.  Novel imaging technologies for genetic diagnoses in the inborn errors of metabolism.

Authors:  Andrea L Gropman; Afrouz Anderson
Journal:  J Transl Genet Genom       Date:  2020-11-13

9.  A Retrospective Case Series Analysis of the Relationship Between Phenylalanine: Tyrosine Ratio and Cerebral Glucose Metabolism in Classical Phenylketonuria and Hyperphenylalaninemia.

Authors:  Colm J McGinnity; Daniela A Riaño Barros; Eric Guedj; Nadine Girard; Christopher Symeon; Helen Walker; Sally F Barrington; Mary Summers; Mervi Pitkanen; Yusof Rahman
Journal:  Front Neurosci       Date:  2021-06-17       Impact factor: 4.677

10.  Evaluation of Tetrahydrobiopterin Therapy with Large Neutral Amino Acid Supplementation in Phenylketonuria: Effects on Potential Peripheral Biomarkers, Melatonin and Dopamine, for Brain Monoamine Neurotransmitters.

Authors:  Shoji Yano; Kathryn Moseley; Xiaowei Fu; Colleen Azen
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.